Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
YOKOHAMA, Japan, May 28, 2013 /PRNewswire/ --
ReproCELL Inc. (CEO: Chikafumi Yokoyama, Ph.D.) announced today that ReproCELL will proceed with an initial public offering (IPO) and has received formal approval from the Osaka Stock Exchange (OSE) for listing on the JASDAQ Market Growth. The listing date is set for June 26th, 2013 (Wednesday). ReproCELL will trade under the OSE listing code 4987.
ReproCELL Inc. was established in 2003 with the goal of contributing to people's health and welfare through the development of stem cell technologies by stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Integrated Cell-Material Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo.
ReproCELL is a world-leading pioneer in commercializing reagents for ES/iPS cells and human pluripotent stem cells as an effective tool for drug discovery and development. The company has successfully launched human iPS cell-derived cardiomyocytes, followed by the launch of human iPS cell-derived neurons, Alzheimer's disease model cells and hepatocytes for drug discovery.
Induced pluripotent stem cells or iPS cells, are a type of pluripotent stem cell artificially derived from a non-pluripotent cell - typically an adult somatic cell. For the discovery of iPS cells, Professor Shinya Yamanaka was awarded the Nobel Prize for Physiology or Medicine in October 2012.
For further information please visit https://www.reprocell.com/en/
Help employers find you! Check out all the jobs and post your resume.